1. Gout Therapeutics - Pipeline Assessment and Market Forecasts to
2019
GlobalData, the industry analysis specialist, has released its new report, “Gout Therapeutics - Pipeline
Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis
on the global Gout Therapeutics market. The report identifies the key trends shaping and driving the
global Gout Therapeutics market. The report also provides insights on the prevalent competitive
landscape and the emerging players expected to significantly alter the market positioning of the current
market leaders. Most importantly, the report provides valuable insights on the pipeline products within
the global Gout Therapeutics sector. This report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of
industry experts.
Scope
The report provides information on the key drivers and challenges of the Gout Therapeutics market. Its
scope includes -
 Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gout
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
 Pipeline analysis data providing a split across the different phases, mechanisms of action being
developed and emerging trends by seven key markets. Pipeline candidates fall under major
therapeutic classes.
 Analysis of the current and future competition in the seven key countries Gout Therapeutics
market.
 Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
 Key topics covered include strategic competitor assessment, market characterization, unmet
needs and the implications for the Gout Therapeutics market.
 Analysis of key recent licensing and partnership agreements in Gout Therapeutics market
Get your copy of this report @ http://www.reportsnreports.com/reports/165255-gout-therapeutics-
pipeline-assessment-and-market-forecasts-to-2019.html
Report Details:
Published: June 2012
No. of Pages: 80
Price: Single User License: US$3995 Corporate User License: US$11985

2. 1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Gout Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Classification 7
2.2.1 Acute Gout 7
2.2.2 Chronic Gout 7
2.3 Epidemiology 8
2.3.1 Historic Epidemiology (2006-2011) 8
2.3.2 Forecast Epidemiology (2011-2019) 8
2.4 Prognosis 9
2.4.1 Progressions of Gout can be Divided into Four Phases 9
2.5 Pathophysiology 10
2.6 Signs and Symptoms 11
2.7 Diagnosis 11
2.7.1 Laboratory Diagnosis Tests 12
2.8 Treatment and Management Options 12
2.8.1 Treatment of Gout in the US 13
2.8.2 Treatment of Gout in Europe 15
2.8.3 Treatment of Gout in Japan 17
2.9 Referral Pathway 18
2.9.1 Referral Pathway in the US 18
2.9.2 Referral Pathway in the Europe 18
2.9.3 Referral Pathway in Japan 18
2.10 GlobalData Pipeline Report Guidance 19
2.11 KOL Insights 20
3 Gout Therapeutics - Market Characterization 21
3.1 Gout Therapeutics Market Size (2006-2011) – Global 21
3.2 Gout Therapeutics Market Forecast (2011-2019) – Global 22
3.3 Gout Therapeutics Market Size (2006-2011) – The US 23
3.4 Gout Therapeutics Market Forecast (2011-2019) – The US 24
3.5 Gout Therapeutics Market Size (2006-2011) – France 25
3.6 Gout Therapeutics Market Forecast (2011-2019) – France 26
3.7 Gout Therapeutics Market Size (2006-2011) – Germany 27
3.8 Gout Therapeutics Market Forecast (2011-2019) – Germany 28
3.9 Gout Therapeutics Market Size (2006-2011) – Italy 29
3.10 Gout Therapeutics Market Forecast (2011-2019) – Italy 30
3.11 Gout Therapeutics Market Size (2006-2011) – Spain 31
3.12 Gout Therapeutics Market Forecast (2011-2019) - Spain 32
3.13 Gout Therapeutics Market Size (2006-2011) – The UK 33
3.14 Gout Therapeutics Market Forecast (2011-2019) – The UK 34
3.15 Gout Therapeutics Market Size (2006-2011) – Japan 35
3.16 Gout Therapeutics Market Forecast (2011-2019) – Japan 36

3. 3.17 Drivers and Barriers for the Gout Therapeutics Market 37
3.17.1 Drivers for the Gout Therapeutics Market 37
3.17.2 Expected Launch of Three Drugs and Consequent Increase in Cost of Therapy 37
3.17.3 Barriers for the Gout Therapeutics Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 KOL Insight: 40
3.20 Key Takeaway 40
4 Gout Therapeutics - Competitive Assessment 41
4.1 Overview 41
4.2 Strategic Competitor Assessment 41
4.3 Product Profiles for the Major Marketed Classes of Products 42
4.3.1 NSAIDs 42
4.3.2 Corticosteroids 43
4.3.3 Colcrys (Colchicines) 43
4.3.4 Allopurinol 44
4.3.5 Probenecid 44
4.3.6 Uloric, Adenuric (febuxostat) 45
4.3.7 Krystexxa (Pegloticase) 46
4.4 KOL Insights 47
4.5 Key Takeaway 47
5 Gout Therapeutics - Pipeline Assessment 48
5.1 Overview 48
5.2 Strategic Pipeline Assessment 48
5.3 Gout Therapeutics Pipeline – Pipeline by Phases of Development 48
5.3.1 Gout Therapeutics – Pre-Registration Phase Pipeline 48
5.3.2 Gout Therapeutics – Phase III Pipeline 49
5.3.3 Gout Therapeutics – Phase II Pipeline 49
5.3.4 Gout Therapeutics – Phase I Pipeline 49
5.3.5 Gout Therapeutics – Pre-Clinical Pipeline 49
5.3.6 Gout Therapeutics – Discovery 50
5.3.7 Technology Trends Analytic Framework 50
5.4 Gout Therapeutics Market – Clinical Pipeline by Mechanism of Action 52
5.5 Gout Therapeutics – Promising Drugs Under Clinical Development 53
5.5.1 Arcalyst (Rilonacept) 53
5.5.2 Ilaris (ACZ885) 54
5.5.3 Lesinurad (RDEA594) 55
5.6 KOL Insights 56
5.7 Key Takeaway 56
6 Gout Therapeutics - Clinical Trials Mapping 57
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 57
6.2 Clinical Trials by Phase 58
6.3 Clinical Trials by Trial Status 59
6.4 Prominent Sponsors 60

4. 6.5 Clinical Trials by Overall Sponsors 61
6.6 Top Companies Participating in Gout Therapeutics Clinical Trials 62
7 Gout Therapeutics - Strategic Assessment 63
7.1 Key Events Impacting the Future Market 63
7.2 Gout Therapeutics: Implications for Future Market Competition 64
8 Gout Therapeutics - Future Players 65
8.1 Introduction 65
8.2 Company Profiles 66
8.2.1 Regeneron Pharmaceuticals, Inc. 66
8.2.2 Novartis AG 66
8.2.3 Ardea Biosciences, Inc 67
8.2.4 Other Companies in the Market 68
9 Gout Therapeutics - Licensing and Partnership Deals 70
10 KOL Insights 74
11 Gout Therapeutics - Appendix 75
11.1 Market Definitions 75
11.2 Abbreviations 75
11.3 Bibliography 76
11.4 Research Methodology 76
11.4.1 Coverage 76
11.4.2 Secondary Research 77
11.4.3 Forecasting 77
11.4.4 Primary Research 79
11.4.5 Expert Panel Validation 80
11.5 Contact Us 80
11.6 Disclaimer 80
Browse all reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-
research/pharmaceuticals/
Contact:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
sales@reportsandreports.com
Connect With Us: